Umberto Malapelle 1 , Marcello Tiseo 2 , Ana Vivancos 3, Joshua Kapp 4, M. Josè Serrano 5,6,7, and Markus Tiemann 8,*. Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective. Molecular Pathology in Solid Tumors. 2021
C. Hoffmann, J.Tepel, M. Tiemann. Morbus Castleman – ein seltenes, heterogenes Krankheitsbild. Best Practice Onkologie 2021
Fehr A. et al. Mucoepidermoid carcinoma of the salivary glands revisited with special reference to histologic grading and CRTC1/3-MAML2 genotyping. Virchows Arch. 2021 Nov;479(5):975-985. doi: 10.1007/s00428-021-03146-x. Epub 2021 Jul 7. PMID: 34231055
Jóri, B.; Schatz, S.; Kaller, L.; Kah, B.; Roeper, J.; Ramdani, H.O.; Diehl, L.; Hoffknecht, P.; Grohé, C.; Griesinger, F.; Tiemann, M.; Heukamp, L.C.; Falk, M. Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy. Cancers 2021, 13(12), 2861
BRAF-Mutated lung cancer, BRAF-mutiertes Lungenkarzinom, BRAF-Mutationssubtypen, BRAF funktionale Klassen, BRAF-Targeted therapy, BRAF mutation functional class, BRAF mutation subtype, BRAF zielgerichtete Therapie, NSCLC immunotherapy, NSCLC Immuntherapie
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy. European Journal of Cancer 2021; DOI: 10.1016/j.ejca.2021.02.036
Mamma carcinoma, Mammakarzinom myoepitheliale Differenzierung, Next-Generation Sequencing (NGS), next generation sequencing (NGS), PIK3CA
Strohkamp et al. Neue Indikation PIK3CA-mutiertes Mammakarzinom: Erste Erfahrungen aus dem molekularpathologischen Routinelabor. Journal Oncologie 2021
Dmitri Atiakshin 1 2 , Igor Buchwalow 3 , Peter Horny 4 , Markus Tiemann 5. Protease profile of normal and neoplastic mast cells in the human bone marrow with special emphasis on systemic mastocytosis. Histochem Cell Biol. 2021 May;155(5):561-580. doi: 10.1007/s00418-021-01964-3. Epub 2021 Jan 25. PMID: 33492488
